| 000 | 01525 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250515032242.0 | ||
| 264 | 0 | _c20061026 | |
| 008 | 200610s 0 0 eng d | ||
| 022 | _a0392-2936 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aArgenta, P A | |
| 245 | 0 | 0 |
_aRadiation therapy with concomitant and adjuvant cisplatin and paclitaxel in high-risk cervical cancer: long-term follow-up. _h[electronic resource] |
| 260 |
_bEuropean journal of gynaecological oncology _c2006 |
||
| 300 |
_a231-5 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aCisplatin _xadministration & dosage |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aDose Fractionation, Radiation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPaclitaxel _xadministration & dosage |
| 650 | 0 | 4 |
_aRadiation-Sensitizing Agents _xtherapeutic use |
| 650 | 0 | 4 | _aRadiotherapy Dosage |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aUterine Cervical Neoplasms _xdrug therapy |
| 700 | 1 | _aGhebre, R | |
| 700 | 1 | _aDusenbery, K E | |
| 700 | 1 | _aChen, M D | |
| 700 | 1 | _aJudson, P L | |
| 700 | 1 | _aDowns, L S | |
| 700 | 1 | _aCarson, L F | |
| 773 | 0 |
_tEuropean journal of gynaecological oncology _gvol. 27 _gno. 3 _gp. 231-5 |
|
| 999 |
_c16393379 _d16393379 |
||